Short revision bullets only, not a replacement for the full lesson sections below.
Toggle for a short revision list before a mock or question block.
Pathophysiology
Clinical meaning
An acute hemolytic transfusion reaction (AHTR) is the most serious and potentially fatal complication of blood transfusion, occurring when pre-formed recipient antibodies (most commonly anti-A or anti-B isohemagglutinins) attack and rapidly destroy transfused donor red blood cells. The vast majority of AHTRs result from ABO incompatibility due to clerical or identification errors -- the wrong blood given to the wrong patient. The mortality rate ranges from 1 in 600,000 to 1 in 1,800,000 transfusions, but when AHTR occurs, the fatality rate approaches 10-44% depending on the volume transfused and the speed of recognition and intervention. The registered nurse is the final safety barrier in the transfusion chain and bears primary responsibility for verifying patient identity, confirming blood compatibility at the bedside, and recognizing the earliest signs of hemolysis.
ABO blood group antigens are carbohydrate structures (oligosaccharides) expressed on the surface of red blood cells, determined by the ABO gene on chromosome 9. Type A individuals have A antigens and naturally occurring anti-B antibodies (IgM class). Type B individuals have B antigens and anti-A antibodies. Type O individuals have neither A nor B antigens but carry both anti-A and anti-B antibodies (making type O the universal donor for red blood cells but the MOST DANGEROUS recipient -- they will hemolyze any non-O blood). Type AB individuals have both A and B antigens with no ABO antibodies (universal recipient). These naturally occurring ABO antibodies are IgM class, which is significant because IgM is an extremely potent activator of the classical complement cascade.
When ABO-incompatible red blood cells are transfused, the recipient's preformed IgM antibodies immediately bind to the foreign ABO antigens on the transfused cells. This antigen-antibody complex activates the classical complement cascade, beginning with C1q binding to the Fc portion of the IgM antibody. The cascade proceeds through C1, C4, C2, and C3, generating the anaphylatoxins C3a and C5a (which cause vasodilation, increased vascular permeability, mast cell degranulation, and neutrophil activation), and culminating in assembly of the membrane attack complex (MAC, C5b-C9) on the surface of the transfused red blood cells. The MAC creates transmembrane pores that cause rapid intravascular hemolysis -- the transfused cells literally explode, releasing their contents directly into the plasma.
The consequences of massive intravascular hemolysis are devastating and multisystemic. Free hemoglobin released into the plasma overwhelms the scavenging capacity of haptoglobin (which normally binds free hemoglobin) and hemopexin (which binds free heme). The excess free hemoglobin is filtered by the glomerulus and precipitates in the renal tubules, causing acute tubular necrosis and acute kidney injury (hemoglobinuric nephropathy). Free hemoglobin also scavenges nitric oxide (a potent vasodilator), causing vasoconstriction, hypertension initially, and then renal vasoconstriction that further impairs renal perfusion. The hemolyzed red blood cells release massive amounts of thromboplastin (tissue factor) and phospholipids that activate the coagulation cascade, triggering disseminated intravascular coagulation (DIC). DIC causes simultaneous widespread microvascular thrombosis (consuming clotting factors and platelets) and hemorrhage (from depleted clotting factors), creating the paradox of concurrent clotting and bleeding.
The anaphylatoxins C3a and C5a generated by complement activation cause systemic vasodilation, increased capillary permeability, bronchospasm, and activation of the inflammatory cascade. C5a is a potent neutrophil chemotaxin, recruiting activated neutrophils that release reactive oxygen species and proteolytic enzymes, causing widespread endothelial damage. Mast cell degranulation releases histamine, causing urticaria, pruritus, flushing, and contributing to hypotension. The massive cytokine release (tumor necrosis factor-alpha, interleukin-1, interleukin-6) produces the systemic inflammatory response that drives fever, tachycardia, and distributive shock.
The clinical presentation of AHTR typically begins within minutes of starting the transfusion (often within the first 15 mL), which is why the registered nurse must remain at the bedside for at minimum the first 15 minutes of any transfusion. The earliest symptoms are often subtle: anxiety, a sense of impending doom, restlessness, chest tightness, or pain at the infusion site. These rapidly progress to fever, chills (rigors), flank pain (from renal capsule distension), low back pain, hemoglobinuria (dark red or cola-colored urine), hypotension, tachycardia, dyspnea, and diffuse bleeding from DIC. In anesthetized or unconscious patients, the first signs may be hemoglobinuria, unexplained hypotension, diffuse oozing from surgical sites (DIC), or fever.
The differential diagnosis includes febrile non-hemolytic transfusion reaction (FNHTR, caused by recipient antibodies against donor leukocyte antigens or cytokines accumulated in stored blood; presents with fever and chills but WITHOUT hemoglobinuria, hypotension, or DIC), allergic/anaphylactic transfusion reaction (urticaria, bronchospasm, angioedema from IgE-mediated allergy to donor plasma proteins; more common in IgA-deficient recipients), transfusion-related acute lung injury (TRALI, non-cardiogenic pulmonary edema from donor antibodies against recipient leukocytes causing neutrophil-mediated lung injury), and bacterial contamination of blood products (gram-negative sepsis with endotoxic shock, more common with platelet transfusion due to room-temperature storage).
The nursing response to suspected AHTR follows an established protocol that must be executed immediately and in the correct order: (1) STOP the transfusion immediately, (2) maintain IV access with normal saline via new tubing (do not flush the blood-contaminated tubing), (3) notify the physician and blood bank simultaneously, (4) verify the patient identity against the blood product label and transfusion tag (clerical check), (5) send the blood bag with attached tubing, post-transfusion blood samples (EDTA tube for DAT/Coombs, and clotted tube), and a fresh urine specimen to the blood bank for investigation, and (6) initiate supportive care as ordered (aggressive IV fluids for renal perfusion, vasopressors for shock, DIC management).
Exam Focus
Exam relevance
Risk factors:
- Clerical or identification errors in blood sampling, labeling, or bedside verification -- responsible for the vast majority of ABO-incompatible transfusions; represents a failure in the final nurse safety check
- History of prior transfusions creating alloantibodies to minor red blood cell antigens (Rh, Kell, Duffy, Kidd systems) that may not be detected on standard crossmatch
- History of pregnancy (exposure to fetal red blood cell antigens during delivery can stimulate maternal antibody production against paternal antigens)
- Sickle cell disease patients who require frequent transfusions and develop alloantibodies at rates of 25-30% due to antigen disparity between predominantly Caucasian donor pools and African American recipients
- Emergency transfusion of uncrossmatched blood (type O negative) where complete compatibility testing has not been performed
- Multiple myeloma or other conditions with paraprotein production that may interfere with compatibility testing
- Immunosuppressed patients whose attenuated immune response may delay clinical recognition of hemolysis
Diagnostics:
- Direct antiglobulin test (DAT/direct Coombs test): detects antibodies or complement bound to the patient's (transfused) red blood cells; positive DAT is the hallmark laboratory finding of immune-mediated hemolysis; a negative DAT does not rule out hemolysis if cells have already been completely destroyed
- Post-transfusion hemoglobin and hematocrit: failure of hemoglobin to rise appropriately after transfusion (expected rise of 1 g/dL per unit of PRBCs) suggests hemolysis or ongoing blood loss
- Plasma free hemoglobin: elevated in intravascular hemolysis; normal plasma is straw-colored; pink or red plasma (hemoglobinemia) is visible evidence of hemolysis
- Haptoglobin level: decreased or undetectable because haptoglobin binds free hemoglobin and the complex is rapidly cleared by the reticuloendothelial system; haptoglobin below 25 mg/dL strongly suggests hemolysis
- Lactate dehydrogenase (LDH): markedly elevated from release of intracellular LDH during red blood cell lysis; LDH is a sensitive but non-specific marker of hemolysis
- DIC panel: fibrinogen (decreased from consumption), D-dimer (elevated from fibrin degradation), PT/INR and aPTT (prolonged from clotting factor consumption), platelet count (decreased from consumption) -- the classic DIC triad of low fibrinogen, high D-dimer, and low platelets
Core concept
Additional clinical detail, exam hooks, and takeaways continue in the full lesson.
Clinical scenario
Additional clinical detail, exam hooks, and takeaways continue in the full lesson.
Takeaways
Additional clinical detail, exam hooks, and takeaways continue in the full lesson.
Unlock full lesson + practice questions
3 more sections with scenarios, priorities, and review drills.
Sample stems (up to the current display cap) from the same NCLEX-RN pool aligned to this lesson—open any item in the app bank or run a full topic drill.
